What GHK-Cu actually does — the plain answer

Ask what GHK-Cu actually does, and the honest one-line answer is short: it tells your body to repair itself.

That’s the whole pitch. A tiny copper-carrying peptide that hands your cells a repair instruction they already know how to read. Your body makes it on its own. It makes less every year. The plan is to top it back up — and the early science says that isn’t a naive thing to want.

So here’s the plain-answer version. What GHK-Cu could do for you, why the biology is worth the interest, and how far the human proof has actually got. The deep dives are linked as we go.

What it actually does

Three things, and none of them are small.

Rebuild skin from underneath. In the lab and in animal skin, GHK-Cu tells the cells to lay down more of the scaffolding that keeps skin firm — and to ease off the enzymes that strip it away. Build up, tear down less. Those are the two things that drift the wrong way as skin ages, pushed back the right way. It’s the best-studied job by a distance, and it has its own full write-up.

Close wounds faster. In animal wounds, GHK-Cu shortens the time tissue takes to knit back together and lays down cleaner repair. This is the oldest thread in the whole research file — the reason anyone started studying it fifty years ago.

Keep the repair system running as you age. Here’s the one that pulls in the longevity crowd. If your body leans on this signal to fix itself, and the signal fades with age, then handing it back might help the whole system keep pace with its own upkeep. That’s the bet. It’s also the job with the least human proof under it — hold that, it matters in a minute.

Put those together and you get a molecule aimed at repair from three directions at once. Firmer skin, faster healing, a body doing maintenance it tends to skip. That’s why one small peptide keeps surfacing in skincare, injury, and longevity threads that otherwise share nothing. The overview map walks all three in one place.

Why it’s worth paying attention to

What lifts GHK-Cu above the average serum ingredient is one fact: your body already makes it.

This isn’t a compound dreamed up in a lab and bolted onto human biology from the outside. It’s a three-part peptide your own blood carries, wrapped around a single copper atom — and the copper is the part that does the work. Why the copper is load-bearing is a story of its own. The short version: plain GHK without it is a different, quieter molecule.

Then there’s the timing. The amount of this peptide in your blood drops steadily as you get older — from roughly 200 nanograms per millilitre in your twenties to about 80 by sixty. Your own stock of a repair signal runs thin over exactly the decades your body could most use it. That single fact is what the whole longevity case stands on. And it’s a real one.

There’s also a hint of how much this molecule reaches. When researchers looked at what it does to gene activity, GHK-Cu shifted the behaviour of thousands of genes at once. Take that as a reason it’s interesting, not as a finished answer. A signal that wide still has to be pinned down before anyone knows what it means inside a living human.

Where the proof runs out

Now the part most sellers skip.

Almost everything above comes from cells and from animals — and much of it from one lab, Loren Pickart’s, four decades deep on this single molecule and not a disinterested party: he holds a commercial stake in it. That’s a genuine track record. It’s also a lot of weight on one group, which isn’t the same evidentiary thing as the result turning up independently across teams with nothing to gain.

GHK-Cu skincare has faced exactly one proper randomised human trial. Miller and colleagues, in 2006, followed thirteen patients healing after laser resurfacing, and the blinded objective scores came back null — no significant difference from placebo on redness, wrinkles, or skin quality. The one measure that came out ahead was the patients’ own rating of their skin, not anything the scorers could see. And that’s the topical side, the strong one. The injected version the performance crowd actually wants has essentially no human data at all: no published pharmacokinetics, no safety file, no dose anyone has properly tested.

So the honest read is hope with clear eyes. The potential is real. The early signals are real. The trials that would settle it haven’t been run. If this turns out as good as the groundwork hints, that’s a serious thing to be early to — and the if is carrying most of the weight.

What the FDA is about to do

Keep the two forms apart, because the rules do. Topical GHK-Cu is sold as a cosmetic and always has been. The injectable form — the vial — is the one the FDA is about to examine.

GHK-Cu isn’t on the FDA’s July 2026 compounding-review wave; that round covers a different set of peptides. It’s booked for the next meeting instead, before the end of February 2027, and specifically the injectable route — the form sold off-label. That’s the one that matters here. Exactly what that review can and can’t decide is its own subject. The headline is plain enough: the form carrying the least evidence is the one about to draw the most scrutiny.

For anyone who gets drug-tested: GHK-Cu isn’t on the WADA prohibited list by name right now. WADA rewrites that list every year, so confirm it against the current code rather than treating this as settled.

What to actually do with this

The plain answer to “what does GHK-Cu actually do” is an exciting one. The plain answer to “where can I get the injectable done right” is, for now, not yet.

That gap is the whole story. What people are buying today is an unlabelled vial from an overseas seller, dosed off guesswork, with nobody to vouch for what’s in it. The version worth waiting for is the same molecule with the guesswork removed: prescribed for a real reason, compounded by a US pharmacy, tested before it reaches you. Building that second version is the entire point of Wolverine Health — and it can’t open until the FDA moves, which is the plain reason it hasn’t.

We’re building the “now.” Tell us where to reach you, and you’ll know the moment “not yet” turns into it.